uniQure (NASDAQ:QURE) Trading Down 4.2% – Here’s Why

Shares of uniQure (NASDAQ:QURE) traded down 4.2% during trading on Thursday . The company traded as low as $12.99 and last traded at $13.08. 453,645 shares traded hands during mid-day trading, a decline of 55% from the average session volume of 1,015,442 shares. The stock had previously closed at $13.65.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on QURE shares. StockNews.com upgraded uniQure to a “sell” rating in a research note on Tuesday, March 11th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research report on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research note on Tuesday, January 21st. Raymond James upgraded shares of uniQure from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. Finally, The Goldman Sachs Group increased their price target on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $38.89.

uniQure Price Performance

The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The company has a market cap of $673.20 million, a P/E ratio of -2.50 and a beta of 0.36. The firm’s fifty day moving average is $13.82 and its two-hundred day moving average is $10.69.

Insider Buying and Selling at uniQure

In other news, CEO Matthew C. Kapusta sold 28,341 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at $6,703,461.66. This represents a 4.17 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Christian Klemt sold 2,916 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the transaction, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This trade represents a 1.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,830 shares of company stock valued at $961,401 in the last three months. 4.74% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC purchased a new position in uniQure during the fourth quarter worth $38,410,000. Franklin Resources Inc. grew its holdings in uniQure by 33.1% during the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company’s stock valued at $35,103,000 after purchasing an additional 494,726 shares during the last quarter. Point72 Asset Management L.P. raised its position in uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock worth $31,282,000 after purchasing an additional 794,459 shares during the period. Integral Health Asset Management LLC lifted its stake in uniQure by 175.0% in the fourth quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock worth $19,426,000 after purchasing an additional 700,000 shares during the last quarter. Finally, RTW Investments LP boosted its position in shares of uniQure by 8,936.3% during the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock valued at $15,958,000 after buying an additional 893,625 shares during the period. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.